CSS
ESLA icon

Cubist Systematic Strategies’s Estrella Immunopharma ESLA Stock Holding History

Cubist Systematic Strategies’s Portfolio ESLA Stock Details ESLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-20,276
Closed -$209K – 4035
2022
Q4 		$209K Sell
20,276
-199,750
-91% -$2.03M ﹤0.01% 3557
2022
Q3 		$2.21M Buy
220,026
+3,131
+1% +$31.5K 0.01% 1903
2022
Q2 		$2.17M Buy
+216,895
New +$2.18M 0.01% 1782

Other funds holding ESLA

HHGC
Hunting Hill Global Capital New York $129M AUM 17.34% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
SIA
SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return
MC
Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return
RCM
Robinson Capital Management Grosse Pointe Farms, Michigan $239M AUM 0.62% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
SOA
Sea Otter Advisors Miami, Florida $1.78M AUM 2.28% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return

Cubist Systematic Strategies's ESLA Position: Q1 2023 in Review

Cubist Systematic Strategies sold out of Estrella Immunopharma (ESLA) in Q1 2023, closing a stake of 20,276 shares — an estimated $209K sold.

Cubist Systematic Strategies first reported a position in ESLA in Q2 2022 and held it in 3 quarters. The position peaked at $2.21M in Q3 2022. 8 funds tracked by Wall St. Rank hold ESLA as of Q1 2023.

  • Cubist Systematic Strategies reported no remaining Estrella Immunopharma position as of Q1 2023 after selling out during the quarter.
  • Cubist Systematic Strategies sold 20,276 Estrella Immunopharma shares in Q1 2023, an estimated $209K.
  • Cubist Systematic Strategies first reported a position in Estrella Immunopharma in Q2 2022 and held it in 3 quarters.
  • Cubist Systematic Strategies's Estrella Immunopharma position peaked at $2.21M in Q3 2022.
  • 8 funds tracked by Wall St. Rank held Estrella Immunopharma as of Q1 2023.

Based on Cubist Systematic Strategies's 13F filing for Q1 2023, filed 15 May 2023.